The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• Hematopoietic progenitor kinase 1 (HPK1) is a key negative regulator of T cell function.
• HPK1 is a target of interest for immunotherapy due to its role in immune regulation.
• Developing specific HPK1 inhibitors is challenging due to kinase family similarities.

Purpose of the Study:

• To identify and characterize a selective and potent chemical probe for HPK1.
• To evaluate the probe's ability to modulate T cell function.

Main Methods:

• Unbiased cellular kinase-binding assays were used to assess probe selectivity.
• In vitro immune cell activation assays were performed to evaluate functional effects.

Main Results:

• A-745 demonstrated excellent cellular selectivity for HPK1 at pharmacologically relevant concentrations.
• Treatment with A-745 resulted in augmented T cell proliferation and cytokine production.
• The observed effects mimicked those of HPK1-deficient or kinase-dead T cells.

Conclusions:

• A-745 serves as a valuable tool for studying HPK1 function in immune cells.
• This selective HPK1 inhibitor provides a foundation for developing new immunotherapies targeting T cell responses.